IBDEI115 ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16743,1,3,0)
 ;;=3^Family Hx of Colonic Polyps
 ;;^UTILITY(U,$J,358.3,16743,1,4,0)
 ;;=4^Z83.71
 ;;^UTILITY(U,$J,358.3,16743,2)
 ;;=^5063386
 ;;^UTILITY(U,$J,358.3,16744,0)
 ;;=Z84.81^^61^776^22
 ;;^UTILITY(U,$J,358.3,16744,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16744,1,3,0)
 ;;=3^Family Hx of Genetic Disease
 ;;^UTILITY(U,$J,358.3,16744,1,4,0)
 ;;=4^Z84.81
 ;;^UTILITY(U,$J,358.3,16744,2)
 ;;=^5063392
 ;;^UTILITY(U,$J,358.3,16745,0)
 ;;=Z86.010^^61^776^70
 ;;^UTILITY(U,$J,358.3,16745,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16745,1,3,0)
 ;;=3^Personal Hx of Colonic Polyps
 ;;^UTILITY(U,$J,358.3,16745,1,4,0)
 ;;=4^Z86.010
 ;;^UTILITY(U,$J,358.3,16745,2)
 ;;=^5063456
 ;;^UTILITY(U,$J,358.3,16746,0)
 ;;=Z86.14^^61^776^75
 ;;^UTILITY(U,$J,358.3,16746,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16746,1,3,0)
 ;;=3^Personal Hx of MRSA Infection
 ;;^UTILITY(U,$J,358.3,16746,1,4,0)
 ;;=4^Z86.14
 ;;^UTILITY(U,$J,358.3,16746,2)
 ;;=^5063464
 ;;^UTILITY(U,$J,358.3,16747,0)
 ;;=Z86.31^^61^776^71
 ;;^UTILITY(U,$J,358.3,16747,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16747,1,3,0)
 ;;=3^Personal Hx of Diabetic Foot Ulcer
 ;;^UTILITY(U,$J,358.3,16747,1,4,0)
 ;;=4^Z86.31
 ;;^UTILITY(U,$J,358.3,16747,2)
 ;;=^5063467
 ;;^UTILITY(U,$J,358.3,16748,0)
 ;;=Z86.711^^61^776^101
 ;;^UTILITY(U,$J,358.3,16748,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16748,1,3,0)
 ;;=3^Personal Hx of Pulmonary Embolism
 ;;^UTILITY(U,$J,358.3,16748,1,4,0)
 ;;=4^Z86.711
 ;;^UTILITY(U,$J,358.3,16748,2)
 ;;=^5063474
 ;;^UTILITY(U,$J,358.3,16749,0)
 ;;=Z86.72^^61^776^107
 ;;^UTILITY(U,$J,358.3,16749,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16749,1,3,0)
 ;;=3^Personal Hx of Thrombophlebitis
 ;;^UTILITY(U,$J,358.3,16749,1,4,0)
 ;;=4^Z86.72
 ;;^UTILITY(U,$J,358.3,16749,2)
 ;;=^5063476
 ;;^UTILITY(U,$J,358.3,16750,0)
 ;;=Z87.310^^61^776^99
 ;;^UTILITY(U,$J,358.3,16750,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16750,1,3,0)
 ;;=3^Personal Hx of Osteoporosis Fx
 ;;^UTILITY(U,$J,358.3,16750,1,4,0)
 ;;=4^Z87.310
 ;;^UTILITY(U,$J,358.3,16750,2)
 ;;=^5063485
 ;;^UTILITY(U,$J,358.3,16751,0)
 ;;=Z87.442^^61^776^110
 ;;^UTILITY(U,$J,358.3,16751,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16751,1,3,0)
 ;;=3^Personal Hx of Urinary Calculi
 ;;^UTILITY(U,$J,358.3,16751,1,4,0)
 ;;=4^Z87.442
 ;;^UTILITY(U,$J,358.3,16751,2)
 ;;=^5063497
 ;;^UTILITY(U,$J,358.3,16752,0)
 ;;=Z87.81^^61^776^108
 ;;^UTILITY(U,$J,358.3,16752,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16752,1,3,0)
 ;;=3^Personal Hx of Traumatic Fx (Healed)
 ;;^UTILITY(U,$J,358.3,16752,1,4,0)
 ;;=4^Z87.81
 ;;^UTILITY(U,$J,358.3,16752,2)
 ;;=^5063513
 ;;^UTILITY(U,$J,358.3,16753,0)
 ;;=Z87.890^^61^776^102
 ;;^UTILITY(U,$J,358.3,16753,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16753,1,3,0)
 ;;=3^Personal Hx of Sex Reassignment
 ;;^UTILITY(U,$J,358.3,16753,1,4,0)
 ;;=4^Z87.890
 ;;^UTILITY(U,$J,358.3,16753,2)
 ;;=^5063517
 ;;^UTILITY(U,$J,358.3,16754,0)
 ;;=Z87.892^^61^776^68
 ;;^UTILITY(U,$J,358.3,16754,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16754,1,3,0)
 ;;=3^Personal Hx of Anaphylaxis
 ;;^UTILITY(U,$J,358.3,16754,1,4,0)
 ;;=4^Z87.892
 ;;^UTILITY(U,$J,358.3,16754,2)
 ;;=^5063519
 ;;^UTILITY(U,$J,358.3,16755,0)
 ;;=Z87.39^^61^776^96
 ;;^UTILITY(U,$J,358.3,16755,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16755,1,3,0)
 ;;=3^Personal Hx of Musculoskeletal/Connective Tissue Disease
